BFG
TEVA icon

Baron Financial Group’s Teva Pharmaceuticals TEVA Stock Holding History

Baron Financial Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,026
Closed -$7.72K – 178
2022
Q2 		$7.72K Hold
1,026
– – 0.01% 159
2022
Q1 		$9.63K Hold
1,026
– – 0.01% 164
2021
Q4 		$8.22K Hold
1,026
– – ﹤0.01% 173
2021
Q3 		$9.99K Buy
1,026
+800
+354% +$7.49K 0.01% 169
2021
Q2 		$2.24K Hold
226
– – ﹤0.01% 220
2021
Q1 		$2.61K Hold
226
– – ﹤0.01% 220
2020
Q4 		$2.18K Hold
226
– – ﹤0.01% 232
2020
Q3 		$2.04K Buy
+226
New +$2.39K ﹤0.01% 238

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Baron Financial Group's TEVA Position: Q3 2022 in Review

Baron Financial Group sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 1,026 shares — an estimated $7.72K sold.

Baron Financial Group first reported a position in TEVA in Q3 2020 and held it in 8 quarters. The position peaked at $9.99K in Q3 2021. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

  • Baron Financial Group reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Baron Financial Group sold 1,026 Teva Pharmaceuticals shares in Q3 2022, an estimated $7.72K.
  • Baron Financial Group first reported a position in Teva Pharmaceuticals in Q3 2020 and held it in 8 quarters.
  • Baron Financial Group's Teva Pharmaceuticals position peaked at $9.99K in Q3 2021.
  • 430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on Baron Financial Group's 13F filing for Q3 2022, filed 3 Nov 2022.